Outlook Therapeutics, Inc. entered into a definitive securities purchase agreement for issuance pf common shares and accompanying warrants for gross proceeds of $65 million on January 23, 2024. The transaction included participation from new lead investor Great Point Partners, LLC, new investors Altium Capital Management LP, Caligan Partners, LP, Schonfeld Strategic Advisors LLC, Sphera Healthcare US Inc., Velan Capital Partners LP, Woodline Partners LP, returning investors Syntone Ventures LLC, Armistice Capital LLC, an undisclosed life science dedicated investor and another existing stockholder. The closing is conditioned upon stockholder approval of the transaction and certain other corporate actions, expected in the first quarter of 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.93 USD | -3.15% | +16.29% | +12.31% |
07-08 | Outlook Therapeutics Receives UK Marketing Authorization for Eye Disease Drug | MT |
07-01 | Outlook Therapeutics, Inc.(NasdaqCM:OTLK) added to Russell Small Cap Comp Value Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.31% | 216M | |
+23.05% | 47.96B | |
+0.63% | 42.45B | |
+43.85% | 41.47B | |
+27.30% | 31.6B | |
+20.70% | 28.63B | |
-6.35% | 28.03B | |
+52.45% | 14.56B | |
+44.36% | 14.14B | |
+2.86% | 12.58B |
- Stock Market
- Equities
- OTLK Stock
- News Outlook Therapeutics, Inc.
- Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors